These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

337 related items for PubMed ID: 18771570

  • 1. New treatments in type 2 diabetes: a focus on the incretin-based therapies.
    Barnett AH.
    Clin Endocrinol (Oxf); 2009 Mar; 70(3):343-53. PubMed ID: 18771570
    [Abstract] [Full Text] [Related]

  • 2. Antidiabetic medications in overweight/obese patients with type 2 diabetes: drawbacks of current drugs and potential advantages of incretin-based treatment on body weight.
    Bonora E.
    Int J Clin Pract Suppl; 2007 Aug; (154):19-28. PubMed ID: 17593274
    [Abstract] [Full Text] [Related]

  • 3. DPP-4 inhibitors and GLP-1 analogues: for whom? Which place for incretins in the management of type 2 diabetic patients?
    Halimi S.
    Diabetes Metab; 2008 Feb; 34 Suppl 2():S91-5. PubMed ID: 18640591
    [Abstract] [Full Text] [Related]

  • 4. Antihyperglycaemic therapy in elderly patients with type 2 diabetes: potential role of incretin mimetics and DPP-4 inhibitors.
    Mathieu C, Bollaerts K.
    Int J Clin Pract Suppl; 2007 Aug; (154):29-37. PubMed ID: 17593275
    [Abstract] [Full Text] [Related]

  • 5. The intersection of safety and adherence: new incretin-based therapies in patients with type 2 diabetes mellitus.
    Zarowitz BJ, Conner C.
    Pharmacotherapy; 2009 Dec; 29(12 Pt 2):55S-67S. PubMed ID: 19947817
    [Abstract] [Full Text] [Related]

  • 6. Incretins and other peptides in the treatment of diabetes.
    Todd JF, Bloom SR.
    Diabet Med; 2007 Mar; 24(3):223-32. PubMed ID: 17263764
    [Abstract] [Full Text] [Related]

  • 7. Incretin mimetics and dipeptidyl peptidase-IV inhibitors: potential new therapies for type 2 diabetes mellitus.
    Triplitt C, Wright A, Chiquette E.
    Pharmacotherapy; 2006 Mar; 26(3):360-74. PubMed ID: 16503716
    [Abstract] [Full Text] [Related]

  • 8. Newly approved and promising antidiabetic agents.
    Combettes M, Kargar C.
    Therapie; 2007 Mar; 62(4):293-310. PubMed ID: 17983555
    [Abstract] [Full Text] [Related]

  • 9. Rationale for dipeptidyl peptidase 4 inhibitors: a new class of oral agents for the treatment of type 2 diabetes mellitus.
    Campbell RK.
    Ann Pharmacother; 2007 Jan; 41(1):51-60. PubMed ID: 17190843
    [Abstract] [Full Text] [Related]

  • 10. Incretin based therapies for type 2 diabetes mellitus.
    Ghosh S, Collier A, Elhadd T, Malik I.
    J Indian Med Assoc; 2008 Jun; 106(6):373-4, 383, 388. PubMed ID: 18839649
    [Abstract] [Full Text] [Related]

  • 11. Incretin-based therapies in type 2 diabetes: a review of clinical results.
    Bosi E, Lucotti P, Setola E, Monti L, Piatti PM.
    Diabetes Res Clin Pract; 2008 Dec 15; 82 Suppl 2():S102-7. PubMed ID: 19022515
    [Abstract] [Full Text] [Related]

  • 12. Replacing SUs with incretin-based therapies for type 2 diabetes mellitus: challenges and feasibility.
    Knop FK, Holst JJ, Vilsbøll T.
    IDrugs; 2008 Jul 15; 11(7):497-501. PubMed ID: 18600596
    [Abstract] [Full Text] [Related]

  • 13. Clinical application of incretin-based therapy: therapeutic potential, patient selection and clinical use.
    Kendall DM, Cuddihy RM, Bergenstal RM.
    Eur J Intern Med; 2009 Jul 15; 20 Suppl 2():S329-39. PubMed ID: 19580952
    [Abstract] [Full Text] [Related]

  • 14. Beyond glycemic control: the effects of incretin hormones in type 2 diabetes.
    Martin CL.
    Diabetes Educ; 2008 Jul 15; 34 Suppl 3():66S-72S. PubMed ID: 18525067
    [Abstract] [Full Text] [Related]

  • 15. The effects of pharmacologic agents for type 2 diabetes mellitus on body weight.
    Pi-Sunyer FX.
    Postgrad Med; 2008 Jul 15; 120(2):5-17. PubMed ID: 18654064
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Incretin-based therapies for type 2 diabetes mellitus: current status and future prospects.
    Drab SR.
    Pharmacotherapy; 2010 Jun 15; 30(6):609-24. PubMed ID: 20500049
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.